How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:OPHT) issued its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.02.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF) , Puma Biotechnology (PBYI) , Incyte (INCY) , Apollo Investment (AINV) , BioMarin Pharmaceutical (BMRN) , (MDVN) (MDVN) , Gilead Sciences (GILD) , Nektar Therapeutics (NKTR) , Bausch Health Companies (BHC) .

NASDAQ:OPHT

IVERIC bio (OPHT) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free OPHT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.13
▼
$1.39
52-Week Range: N/A

Volume: N/A
Average Volume: 159,109 shs
Market Capitalization: $1.65 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get IVERIC bio alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About IVERIC bio Stock (NASDAQ:OPHT)

IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

OPHT Stock News Headlines

November 5, 2023 | morningstar.com

Gossamer Bio Inc GOSS

June 30, 2023 | msn.com

Iveric Bio ticks higher as it sees sale to Astellas closing July 11

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

June 29, 2023 | msn.com

Iveric Bio falls amid concern about Astellas deal

May 6, 2023 | msn.com

Baird Downgrades IVERIC bio (ISEE)

May 6, 2023 | msn.com

Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio

May 2, 2023 | msn.com

Iveric Bio (NASDAQ:ISEE) Sold for $5.9B

May 1, 2023 | msn.com

Astellas to Buy Eye-Drug Maker Iveric Bio for $5.9 Billion

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

May 1, 2023 | reuters.com

Astellas Pharma buys Iveric Bio for $5.9 billion

April 30, 2023 | msn.com

Astellas Pharma to Buy Iveric Bio for $5.9 Billion

April 30, 2023 | wsj.com

Astellas Pharma to Buy Iveric Bio for About $5.9B

April 30, 2023 | msn.com

Astellas Pharma agrees to buy Iveric Bio for $5.9 Billion

March 3, 2023 | markets.businessinsider.com

Robert W. Baird Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

March 1, 2023 | marketwatch.com

IVERIC Bio Shares Up 14% After Positive Trial Results, 4Q Losses

February 17, 2023 | marketwatch.com

Iveric Bio Shares Rise 16% After FDA Accepts New Drug App for Avacincaptad Pegol

February 16, 2023 | nasdaq.com

Deep Track Capital Now Owns 5.88% of IVERIC bio (ISEE)

February 16, 2023 | nasdaq.com

Rtw Investments Now Owns 0.60% of IVERIC bio (ISEE)

September 16, 2022 | seekingalpha.com

ISEE IVERIC bio, Inc.

September 7, 2022 | markets.businessinsider.com

Where IVERIC bio Stands With Analysts

August 25, 2022 | markets.businessinsider.com

Iveric Bio To Announce GATHER2 Trial Data In September

January 18, 2022 | thestreet.com

Why Ophthotech (OPHT) Stock Is Surging Today

August 9, 2021 | seekingalpha.com

IVERIC bio, Inc. 2021 Q2 - Results - Earnings Call Presentation

See More Headlines

Receive OPHT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/31/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OPHT
CUSIP: N/A
CIK: 1410939
Web: www.ophthotech.com
Phone: (212) 845-8200
Fax: N/A
Employees: 35
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $63.09 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -141.53%
Return on Assets: -41.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.09
Quick Ratio: 10.09

Sales & Book Value

Annual Sales: $209.98 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.00 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 41,420,000
Free Float: N/A
Market Cap: $1.65 billion
Optionable: Optionable
Beta: 1.49

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Glenn P. Sblendorio
President, Chief Executive Officer & Director
Keith Westby
Chief Operating Officer & Senior Vice President
David F. Carroll
Chief Financial Officer, Treasurer & SVP
Kourous A. Rezaei
Chief Medical Officer & Senior Vice President
Abraham Scaria
Chief Scientific Officer

Key Competitors

View All Competitors

OPHT Stock Analysis - Frequently Asked Questions

How were IVERIC bio's earnings last quarter?: IVERIC bio, Inc. (NASDAQ:OPHT) issued its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.02.
What other stocks do shareholders of IVERIC bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC).

This page (NASDAQ:OPHT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IVERIC bio (OPHT) Stock Price, News & Analysis

About IVERIC bio Stock (NASDAQ:OPHT)

OPHT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OPHT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info